search
Back to results

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33)

Primary Purpose

Ovarian Cancer

Status
Recruiting
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
Niraparib
Dostarlimab
Pegylated liposomal doxorubicin
Paclitaxel
Gemcitabine
Topotecan
Bevacizumab
Sponsored by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ovarian Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Participant must have recurrent ovarian, Fallopian tube or primary peritoneal cancer not candidate for platinum retreatment; and in particular

    • platinum resistant patients (platinum-free interval 1-6 months from last dose of platinum)
    • patients for which platinum is contraindicated because of previous allergic reactions or residual toxicity (i.e nephrotoxicity or neurotoxicity)
    • patients not able( in physician's opinion) to receive further platinum or not willing (in patients' opinion) to receive further platinum
  2. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
  3. Participants must have measurable disease or evaluable based on RECIST 1.1 (patients with only CA 125 increase without evidence of disease are not included).
  4. Participant must be ≥ 18 years of age
  5. Participant must have adequate organ function
  6. Participant receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy.
  7. Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
  8. Participants must agree to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1.

    Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen.

  9. Female participant has a negative urine or serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or is of nonchildbearing potential.
  10. Participant must agree to not breastfeed during the study or for 180 days after the last dose of study treatment.
  11. Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent

Exclusion Criteria:

  1. Participant must not be simultaneously enrolled in any interventional clinical trial
  2. Participants have received >2 previous CHT lines (previous treatment with parp inhibitors and/or anti check point inhibitors is allowed providing that at least 6 months from last treatment are intercurred)
  3. Participant must not have had major surgery ≤ 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects.
  4. Participant must not have received investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.
  5. Participant has had radiation therapy encompassing >20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy.
  6. Participant must not have a known hypersensitivity to niraparib and dostarlimab components or excipients.
  7. Participant must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating protocol therapy.
  8. Participant must not have received colony-stimulating factors (eg, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.
  9. Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment.
  10. Participant must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
  11. Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent
  12. Participant must not have had diagnosis, detection, or treatment of another type of cancer ≤ 3 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)
  13. Participant must not have known, symptomatic brain or leptomeningeal metastases
  14. Patient experienced ≥ Grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.
  15. Participant has a diagnosis of immunodeficiency or has received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy.
  16. Participant has a known history of human immunodeficiency virus (type 1 or 2 antibodies).
  17. Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected).
  18. Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  19. Participant must not have a history of interstitial lung disease.
  20. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  21. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines are live attenuated vaccines, and are not allowed.

Sites / Locations

  • Azienda Ospedaliera Spedali CiviliRecruiting
  • Istituto Tumori della Romagna IRST IRCCSRecruiting
  • IEO-Istituto Europeo di OncologiaRecruiting
  • IRCCS Ospedale San RaffaeleRecruiting
  • Istituto Nazionale Tumori IRCCS Fondazione G. PascaleRecruiting
  • Nuovo Ospedale degli InfermiRecruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCSRecruiting
  • Istituti fisioterapici Ospitalieri - Istituto Tumori Regina ElenaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Phisician's choice of standard chemotherapy

Niraparib+Dostarlimab

Arm Description

Chemotherapy at physician's choice between Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 Gemcitabine 1000 mg/mq d 1,8,15 q 28 Topotecan 1.25 mg/mq day 1-5 q 21 +/- Bevacizumab at defined scehedule

Dostarlimab 500 mg q 3W for the fist 4 cycles, 1000 mg q 6W thereafter + Niraparib 300 mg or 200 mg if platelet count <150,000 /μL and/or body weight <77kg QD po q 28

Outcomes

Primary Outcome Measures

Overall Survival
The length of time from tfrom the date of randomization to the date of death by any cause

Secondary Outcome Measures

Progression free survival
the length of time from the date of randomization to the earlier date of assessment of progression or death by any cause in the absence of progression.
Time to first subsequent therapy
The length of the time interval from the date of randomization to earliest date of fist subsequent therapy or death
Response rate
the percentage of patients with CR or PR, as assessed by RECIST (Response Evaluation Criteria on Solid Tumor) v.1.1 criteria evaluated by the investigator.
Number and type of adverse events
Safety and tolerability of patients receiving chemotherapy or dostarlimab plus niraparib evaluated according to CTCAE vers 5.0.
Patient-reported outcomes for physical well-being
quality of life of patients, in terms of physical well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ C30 (Quality of life Questionnaires C30). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Patient-reported outcomes for physical well-being
quality of life of patients, in terms of physical well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ OV28 (Quality of life Questionnaires OV28). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Patient-reported outcomes for physical well-being
quality of life of patients, in terms of physical well-being, evaluated using EQ-5DL (EURO-QOL). "0" is the minimum score and is the worse outcome, "100" is the maximum score and is the better outcome.
Patient-reported outcomes for social/family well-being
quality of life of patients, in terms of social/family well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ C30 (Quality of life Questionnaires C30). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Patient-reported outcomes for social/family well-being
quality of life of patients, in terms of social/family well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ OV28 (Quality of life Questionnaires OV28). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Patient-reported outcomes for social/family well-being
quality of life of patients, in terms of social/family well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) EQ-5DL (EURO-QOL). "0" is the minimum score and is the worse outcome, "100" is the maximum score and is the better outcome.
Patient-reported outcomes for emotional well-being
quality of life of patients, in terms of emotional well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ C30 (Quality of life Questionnaires C30). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Patient-reported outcomes for emotional well-being
quality of life of patients, in terms of emotional well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ OV28 (Quality of life Questionnaires OV28). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Patient-reported outcomes for emotional well-being
quality of life of patients, in terms of emotional well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) EQ-5DL (EURO-QOL). "0" is the minimum score and is the worse outcome, "100" is the maximum score and is the better outcome.

Full Information

First Posted
October 5, 2020
Last Updated
August 24, 2021
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT04679064
Brief Title
Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Acronym
NItCHE-MITO33
Official Title
Randomized Phase III Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment: NItCHE Trial (MITO 33)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators
GlaxoSmithKline

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician's choice in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer patients for which platinum is not an option
Detailed Description
Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician's choice in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer patients for which platinum is not an option. The patients must have received no more than 2 previous chemotherapy lines. Stratification factors will include HRD status, previous treatment with parp and anti PD-1/PDL-1 inhibitors, Bevacizumab treatment and PDL1 expression. Patients will continue to receive niraparib until disease progression (determined using RECIST v.1.1 criteria and clinical criteria), unacceptable toxicity, death, withdrawal of consent, or lost to follow-up, whichever comes first. Patients will continue to receive dostarlimab for a maximum of 2 years, or until disease progression (determined using RECIST v1.1 criteria and clinical criteria), unacceptable toxicity, death, withdrawal of consent, lost to follow-up, whichever may come first. Dose interruption and/or reduction may be implemented at any time for any grade toxicity considered intolerable by the patient.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
427 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phisician's choice of standard chemotherapy
Arm Type
Active Comparator
Arm Description
Chemotherapy at physician's choice between Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 Gemcitabine 1000 mg/mq d 1,8,15 q 28 Topotecan 1.25 mg/mq day 1-5 q 21 +/- Bevacizumab at defined scehedule
Arm Title
Niraparib+Dostarlimab
Arm Type
Experimental
Arm Description
Dostarlimab 500 mg q 3W for the fist 4 cycles, 1000 mg q 6W thereafter + Niraparib 300 mg or 200 mg if platelet count <150,000 /μL and/or body weight <77kg QD po q 28
Intervention Type
Drug
Intervention Name(s)
Niraparib
Other Intervention Name(s)
Zejula
Intervention Description
PARP-inihibitor
Intervention Type
Drug
Intervention Name(s)
Dostarlimab
Other Intervention Name(s)
TSR-042
Intervention Description
PD-1 inihibitor
Intervention Type
Drug
Intervention Name(s)
Pegylated liposomal doxorubicin
Intervention Description
Chemotherapy drug
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
Chemotherapy drug
Intervention Type
Drug
Intervention Name(s)
Gemcitabine
Intervention Description
Chemotherapy drug
Intervention Type
Drug
Intervention Name(s)
Topotecan
Intervention Description
Chemotherapy drug
Intervention Type
Drug
Intervention Name(s)
Bevacizumab
Other Intervention Name(s)
Avastin
Intervention Description
Chemotherapy drug
Primary Outcome Measure Information:
Title
Overall Survival
Description
The length of time from tfrom the date of randomization to the date of death by any cause
Time Frame
4 years
Secondary Outcome Measure Information:
Title
Progression free survival
Description
the length of time from the date of randomization to the earlier date of assessment of progression or death by any cause in the absence of progression.
Time Frame
4 years
Title
Time to first subsequent therapy
Description
The length of the time interval from the date of randomization to earliest date of fist subsequent therapy or death
Time Frame
4 years
Title
Response rate
Description
the percentage of patients with CR or PR, as assessed by RECIST (Response Evaluation Criteria on Solid Tumor) v.1.1 criteria evaluated by the investigator.
Time Frame
4 years
Title
Number and type of adverse events
Description
Safety and tolerability of patients receiving chemotherapy or dostarlimab plus niraparib evaluated according to CTCAE vers 5.0.
Time Frame
4 years
Title
Patient-reported outcomes for physical well-being
Description
quality of life of patients, in terms of physical well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ C30 (Quality of life Questionnaires C30). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Time Frame
4 years
Title
Patient-reported outcomes for physical well-being
Description
quality of life of patients, in terms of physical well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ OV28 (Quality of life Questionnaires OV28). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Time Frame
4 years
Title
Patient-reported outcomes for physical well-being
Description
quality of life of patients, in terms of physical well-being, evaluated using EQ-5DL (EURO-QOL). "0" is the minimum score and is the worse outcome, "100" is the maximum score and is the better outcome.
Time Frame
4 years
Title
Patient-reported outcomes for social/family well-being
Description
quality of life of patients, in terms of social/family well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ C30 (Quality of life Questionnaires C30). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Time Frame
4 years
Title
Patient-reported outcomes for social/family well-being
Description
quality of life of patients, in terms of social/family well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ OV28 (Quality of life Questionnaires OV28). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Time Frame
4 years
Title
Patient-reported outcomes for social/family well-being
Description
quality of life of patients, in terms of social/family well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) EQ-5DL (EURO-QOL). "0" is the minimum score and is the worse outcome, "100" is the maximum score and is the better outcome.
Time Frame
4 years
Title
Patient-reported outcomes for emotional well-being
Description
quality of life of patients, in terms of emotional well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ C30 (Quality of life Questionnaires C30). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Time Frame
4 years
Title
Patient-reported outcomes for emotional well-being
Description
quality of life of patients, in terms of emotional well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) QLQ OV28 (Quality of life Questionnaires OV28). "1" is the minimum score and is the better outcome, "4" is the maximum score and is the worse outcome.
Time Frame
4 years
Title
Patient-reported outcomes for emotional well-being
Description
quality of life of patients, in terms of emotional well-being, evaluated using EORTC (European Organization for Research and Treatment of Cancer) EQ-5DL (EURO-QOL). "0" is the minimum score and is the worse outcome, "100" is the maximum score and is the better outcome.
Time Frame
4 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participant must have recurrent ovarian, Fallopian tube or primary peritoneal cancer not candidate for platinum retreatment; and in particular platinum resistant patients (platinum-free interval 1-6 months from last dose of platinum) patients for which platinum is contraindicated because of previous allergic reactions or residual toxicity (i.e nephrotoxicity or neurotoxicity) patients not able( in physician's opinion) to receive further platinum or not willing (in patients' opinion) to receive further platinum Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 Participants must have measurable disease or evaluable based on RECIST 1.1 (patients with only CA 125 increase without evidence of disease are not included). Participant must be ≥ 18 years of age Participant must have adequate organ function Participant receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy. Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment. Participants must agree to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen. Female participant has a negative urine or serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment, or is of nonchildbearing potential. Participant must agree to not breastfeed during the study or for 180 days after the last dose of study treatment. Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent Exclusion Criteria: Participant must not be simultaneously enrolled in any interventional clinical trial Participants have received >2 previous CHT lines (previous treatment with parp inhibitors and/or anti check point inhibitors is allowed providing that at least 6 months from last treatment are intercurred) Participant must not have had major surgery ≤ 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects. Participant must not have received investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy. Participant has had radiation therapy encompassing >20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy. Participant must not have a known hypersensitivity to niraparib and dostarlimab components or excipients. Participant must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating protocol therapy. Participant must not have received colony-stimulating factors (eg, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy. Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment. Participant must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent Participant must not have had diagnosis, detection, or treatment of another type of cancer ≤ 3 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated) Participant must not have known, symptomatic brain or leptomeningeal metastases Patient experienced ≥ Grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities. Participant has a diagnosis of immunodeficiency or has received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy. Participant has a known history of human immunodeficiency virus (type 1 or 2 antibodies). Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected). Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Participant must not have a history of interstitial lung disease. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines are live attenuated vaccines, and are not allowed.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Domenica Lorusso, MD
Phone
0630158545
Ext
0630158545
Email
domenica.lorusso@policlinicogemelli.it
First Name & Middle Initial & Last Name or Official Title & Degree
Serena Giolitto, MSc
Phone
0630158545
Ext
0630158545
Email
serena.giolitto@policlinicogemelli.it
Facility Information:
Facility Name
Azienda Ospedaliera Spedali Civili
City
Brescia
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto Tumori della Romagna IRST IRCCS
City
Meldola
Country
Italy
Individual Site Status
Recruiting
Facility Name
IEO-Istituto Europeo di Oncologia
City
Milan
Country
Italy
Individual Site Status
Recruiting
Facility Name
IRCCS Ospedale San Raffaele
City
Milan
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
City
Naples
Country
Italy
Individual Site Status
Recruiting
Facility Name
Nuovo Ospedale degli Infermi
City
Ponderano
Country
Italy
Individual Site Status
Recruiting
Facility Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
City
Rome
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Domenica Lorusso, MD
Phone
0630158545
Ext
0630158545
Email
domenica.lorusso@policlinicogemelli.it
First Name & Middle Initial & Last Name & Degree
Serena Giolitto, MSc
Phone
0630158545
Ext
0630158545
Email
serena.giolitto@policlinicogemelli.it
Facility Name
Istituti fisioterapici Ospitalieri - Istituto Tumori Regina Elena
City
Rome
Country
Italy
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34607820
Citation
Musacchio L, Salutari V, Pignata S, Braicu E, Cibula D, Colombo N, Frenel JS, Zagouri F, Carbone V, Ghizzoni V, Giolitto S, Giudice E, Perri MT, Ricci C, Scambia G, Lorusso D. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). Int J Gynecol Cancer. 2021 Oct;31(10):1369-1373. doi: 10.1136/ijgc-2021-002593.
Results Reference
derived

Learn more about this trial

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

We'll reach out to this number within 24 hrs